North America
US global headquarters in Wyoming plus Canada — FDA-aware pharma, medtech, and cross-industry programmes with harmonised North American readouts.
Report = dedicated country page. Other countries link to our full coverage index.
BioNixus is a global insights and market research partner spanning the Americas, EMEA, and APAC — with country-level depth in every market that matters to your P&L. From life sciences to B2B, consumer, and industrial categories, we help leadership teams convert primary evidence — physician and payer intelligence, hospital and channel dynamics, KOL and customer insight — into clear decisions on launch, access, expansion, and portfolio priority.
The site is built as two linked silos: a regulated healthcare silo and a non-healthcare industries silo. This hub is the bridge between them.
Read this page in your language: English · Deutsch · Français · Español · 中文 · العربية · Português · Русский
Pick the segment that matches your decision and go straight to the depth you need. Each one runs to the same standard BioNixus built in healthcare.
Pharmaceutical and healthcare research is the discipline BioNixus was founded on in London in 2012, and it remains the core of the firm. Everything else we do in B2B and B2C markets borrows the standards we set here: verified respondents, defensible sampling, and evidence built for a decision rather than a slide library.
Enter Pharma & Healthcare →B2B decisions turn on a small number of high-value buyers, long sales cycles, and committees rather than crowds. BioNixus brings the same sampling discipline and senior-led analysis we built in healthcare to technology, energy, real estate, public sector, and education research.
Enter B2B Industries →Consumer markets move on perception, habit, and price sensitivity at scale. BioNixus measures what drives choice — across FMCG, retail, financial services, telecom, automotive, hospitality, and media — with samples that represent the real population, not an open-internet opt-in pool.
Enter B2C Industries →Fieldwork-led articles for non-healthcare buyers — filter by industry vertical and country on our dedicated insights index. Healthcare and pharmaceutical research stays on our dedicated healthcare blog.
3 published articles · GCC & MENA focus
BioNixus is US-headquartered in Sheridan, Wyoming, with research operations in London and Cairo. That structure lets us run American, European, LATAM, and APAC programmes to the same standard as our MENA fieldwork — and benchmark a launch or a brand across every region inside a single evidence framework.
In Latin America, Portuguese and Spanish field teams support ANVISA-aware pharma, hospital procurement, and consumer programmes across Brazil and harmonised multi-country LATAM readouts. In Asia-Pacific, local moderators and hospital networks field PMDA-, NMPA-, and CDSCO-aware designs for Japan, China, India, South Korea, Singapore, and Australia — with the same governance applied to our B2B industries and B2C industries work, and a direct line back to the healthcare market research hub where the firm began.
US global headquarters in Wyoming plus Canada — FDA-aware pharma, medtech, and cross-industry programmes with harmonised North American readouts.
Report = dedicated country page. Other countries link to our full coverage index.
Portuguese and Spanish field teams across Brazil, Mexico, Colombia, and Andean markets — ANVISA-aware pharma, hospital procurement, and consumer research with bilingual moderation.
London regional office and coordinated EU5+ fieldwork for HTA-aware pharmaceutical research and B2B/B2C industry programmes.
Deep GCC heritage with country offices, regulator-aware pharmaceutical research, and the fullest sixteen-industry matrix coverage.
Cairo regional hub and pan-African field partners for hospital, payer, and consumer research beyond North Africa.
APAC pharmaceutical and industry research through local moderators, hospital networks, and payer-aware mixed-method designs.
BioNixus organises its work into three segments: pharma & healthcare (pharma, MedTech, hospitals, biotech, and consumer health), B2B (technology, energy, real estate, public sector, and education), and B2C (FMCG, retail, automotive, hospitality, media, telecom, and financial services).
No. Healthcare and pharmaceutical research is where BioNixus was founded in London in 2012 and where it leads, but the same sampling discipline and senior-led analysis now extend to B2B and B2C categories through the B2B industries and B2C industries sections.
BioNixus was founded in London in 2012, is US-headquartered in Sheridan, Wyoming, and runs MENA programmes from a regional office in Greater Cairo. That footprint supports programmes across North America, LATAM, Europe, the GCC, Africa, and APAC under one evidence framework — with bilingual Arabic–English fieldwork in MENA and Portuguese and Spanish moderation in Latin America.
This hub is the deliberate bridge between them. The pharma & healthcare silo links to deep country and therapy coverage, while the B2B and B2C sections apply the same standards to non-healthcare categories. Use the segment cards above to enter the section you need.
Tell us the decision in front of you. We will scope the evidence to match it.